About | Free Trial

Last Update

2015-02-09T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Marcia Keen?

Dr. Marcia Keen

Senior Manager

Amgen Inc.

HQ Phone: (805) 447-1000

Amgen Inc.

One Amgen Center Drive

Thousand Oaks, California 91320

United States

Company Description

Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular ... more

Find other employees at this company (22,105)

Background Information

Employment History

Research Nurse
Ralph K. Davies Medical Center

RN
Hemodialysis Adequacy Work Group

Affiliations

Member of the Steering Committee
National Institutes of Health-sponsored HEMO trial

Member of the Writing Committee
RPA Clinical Practice Guideline

Education

MS

PhD

doctorate

University of California , San Francisco

Web References (8 Total References)


QMS February 2010 Newsletter

www.qms-us.com [cached]

It began with a discussion regarding Vascular Access by Dr. Marcia Keen, RN, PhD, CNN, Research Nurse at Ralph K. Davies Medical Center, San Francisco, as well as Amgen and project manager for The DOPPS study. Dr. Keen's session touched on the fact that the U.S. is behind most other countries in regards to the goals for the number of fistulas used as a primary access for dialysis patients, especially for patients starting dialysis. The effect of this has contributed to lower quality outcomes for U.S. patients including a higher mortality rate overall compared to the rest of the world as well as higher hospitalization rates. There are several aspects to this problem for the U.S. One is that because of the lack of insurance coverage for a large number of pre-ESRD patients many of them are not worked up prior to going on dialysis and consequently a fistula is not placed early. Another issue is that in comparison to other countries, U.S. vascular surgeons do not have extensive training or experience in fistula creation as is the case in other countries; this factor appears to be associated with high problem rates. Specific QCS reports were discussed in a workshop format to help attendees understand the data available in QCS to evaluate this issue in their clinics.

Following Dr. Keen's discussion, Diana Hlebovy, RN, BSN, CHN, CNN, Clinical Director of HemaMetrics, and a recognized expert on fluid management, discussed the rationale for emphasizing fluid management in the Conditions for Coverage.


QMS February 2010 Newsletter

www.qms-us.com [cached]

It began with a discussion regarding Vascular Access by Dr. Marcia Keen, RN, PhD, CNN, Research Nurse at Ralph K. Davies Medical Center, San Francisco, as well as Amgen and project manager for The DOPPS study. Dr. Keen's session touched on the fact that the U.S. is behind most other countries in regards to the goals for the number of fistulas used as a primary access for dialysis patients, especially for patients starting dialysis. The effect of this has contributed to lower quality outcomes for U.S. patients including a higher mortality rate overall compared to the rest of the world as well as higher hospitalization rates. There are several aspects to this problem for the U.S. One is that because of the lack of insurance coverage for a large number of pre-ESRD patients many of them are not worked up prior to going on dialysis and consequently a fistula is not placed early. Another issue is that in comparison to other countries, U.S. vascular surgeons do not have extensive training or experience in fistula creation as is the case in other countries; this factor appears to be associated with high problem rates. Specific QCS reports were discussed in a workshop format to help attendees understand the data available in QCS to evaluate this issue in their clinics.

Following Dr. Keen's discussion, Diana Hlebovy, RN, BSN, CHN, CNN, Clinical Director of HemaMetrics, and a recognized expert on fluid management, discussed the rationale for emphasizing fluid management in the Conditions for Coverage.


QMS February 2010 Newsletter

qms-us.com [cached]

It began with a discussion regarding Vascular Access by Dr. Marcia Keen, RN, PhD, CNN, Research Nurse at Ralph K. Davies Medical Center, San Francisco, as well as Amgen and project manager for The DOPPS study. Dr. Keen's session touched on the fact that the U.S. is behind most other countries in regards to the goals for the number of fistulas used as a primary access for dialysis patients, especially for patients starting dialysis. The effect of this has contributed to lower quality outcomes for U.S. patients including a higher mortality rate overall compared to the rest of the world as well as higher hospitalization rates. There are several aspects to this problem for the U.S. One is that because of the lack of insurance coverage for a large number of pre-ESRD patients many of them are not worked up prior to going on dialysis and consequently a fistula is not placed early. Another issue is that in comparison to other countries, U.S. vascular surgeons do not have extensive training or experience in fistula creation as is the case in other countries; this factor appears to be associated with high problem rates. Specific QCS reports were discussed in a workshop format to help attendees understand the data available in QCS to evaluate this issue in their clinics.

Following Dr. Keen's discussion, Diana Hlebovy, RN, BSN, CHN, CNN, Clinical Director of HemaMetrics, and a recognized expert on fluid management, discussed the rationale for emphasizing fluid management in the Conditions for Coverage.


K/DOQI Update 2000

www.kidney.org [cached]

,Marcia Keen, PhD, MS, RN, is Senior Manager, Nephrology professional Services at Amgen Inc. She has been actively involved in dialysis patient care and clinical research for a number of years. Her research interests have included quantification techniques for hemodialysis and peritoneal dialysis therapy, anticoagulation control in hemodialysis, and vascular access. Her published work includes book chapters and research reports in a number of professional journals. She is a member of the Steering Committee for the National Institutes of Health-sponsored HEMO trial. She was a member of the writing committee for the RPA Clinical Practice Guideline on Adequacy of Hemodialysis. She completed her doctorate at the University of California, San Francisco, in volume and osmolity control in hemodialysis patients.


K/DOQI Update 2000

www.kidney.org [cached]

Marcia Keen, PhD, MS, RN, is Senior Manager, Nephrology professional Services at Amgen Inc. She has been actively involved in dialysis patient care and clinical research for a number of years. Her research interests have included quantification techniques for hemodialysis and peritoneal dialysis therapy, anticoagulation control in hemodialysis, and vascular access. Her published work includes book chapters and research reports in a number of professional journals. She is a member of the Steering Committee for the National Institutes of Health-sponsored HEMO trial. She was a member of the writing committee for the RPA Clinical Practice Guideline on Adequacy of Hemodialysis. She completed her doctorate at the University of California, San Francisco, in volume and osmolity control in hemodialysis patients.

Similar Profiles

Other People with this Name

Other people with the name Keen

Grant Keen
Eurofreight Shipping Agencies Ltd

Donna Keen
Lake Cumberland District Health Department

Jamie Keen
Scenic Regional Library

Harry Keen
District Museum and Archives

Lisa Keen
Keen News Service LLC

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory